Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2
Top Cited Papers
- 30 June 2006
- journal article
- research article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 44 (6), 1167-1174
- https://doi.org/10.1016/j.jhep.2006.02.011
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- CCR2 modulates inflammatory and metabolic effects of high-fat feedingJCI Insight, 2006
- Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver diseaseScandinavian Journal of Gastroenterology, 2005
- The Inflammatory SyndromeJournal of the American Society of Nephrology, 2004
- Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver diseaseHepatology, 2004
- Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndromeHepatology, 2003
- Hepatic Expression of Secondary Lymphoid Chemokine (CCL21) Promotes the Development of Portal-Associated Lymphoid Tissue in Chronic Inflammatory Liver DiseaseThe American Journal of Pathology, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆Gastroenterology, 1999
- Steatohepatitis: A tale of two “hits”?Gastroenterology, 1998
- Monocyte-chemoattractant protein 1 gene expression in intestinal epithelial cells and inflammatory bowel disease mucosaGastroenterology, 1995